Holen Sie sich die Stockscreener-App
105.46
1.61%
-1.73
Handel nachbörslich:
106.37
0.91
+0.86%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$107.19
Offen:
$107.04
24-Stunden-Volumen:
81.59M
Relative Volume:
7.72
Marktkapitalisierung:
$183.26B
Einnahmen:
$44.33B
Nettoeinkommen (Verlust:
$6.50B
KGV:
28.37
EPS:
3.717
Netto-Cashflow:
$7.40B
1W Leistung:
-2.38%
1M Leistung:
-6.02%
6M Leistung:
-22.48%
1J Leistung:
-16.82%
1-Tages-Spanne:
$105.40
$107.79
1-Wochen-Bereich:
$105.40
$111.86
52-Wochen-Spanne:
$105.27
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
105.46 | 183.26B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
335.67 | 128.46B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.16 | 110.62B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
69.48 | 103.10B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.50 | 47.92B | 6.07B | 1.06B | 1.34B | 1.8063 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
St. Louis Financial Planners Asset Management LLC Purchases New Position in Abbott Laboratories $ABT - MarketBeat
Abbott Labs’ $23 billion deal to acquire Madison’s Exact Sciences set to close Monday - Wisconsin State Journal
Abbott Laboratories $ABT Shares Purchased by Covea Finance - MarketBeat
Abbott Laboratories Finalizes Major Acquisition in Cancer Diagnostics - AD HOC NEWS
Is Abbott Laboratories (ABT) Share Price Weakness Creating A Long Term Opportunity? - simplywall.st
Abbott Laboratories to close on Exact Sciences purchase - Channel 3000
Abbott (NYSE:ABT) Expands Diagnostics With Exact Sciences Amid S&P 500 Futures - Kalkine Media
Exact Sciences and Abbott receive all approvals for planned merger By Investing.com - Investing.com India
Abbott Laboratories’ CGM Growth Story Looks Obvious—But the NEXT Leg Is Even Bigger! - Smartkarma
Abbott Laboratories to close $21B Exact Sciences deal Monday - Modern Healthcare
When Abbott Labs expects to close on $23B takeover of Exact Sciences - The Business Journals
Abbott expects to close on acquisition of Madison’s Exact Sciences on Monday - WPR
Abbott closing Exact Sciences acquisition next week - Channel 3000
Abbott, Boston Scientific Oppose Spinal Cord Stimulator Lawsuit MDL - AboutLawsuits.com
Exact Sciences Corp Announces Merger Agreement with Abbott Laboratories – SEC 8-K Filing March 2026 - Minichart
Abbott to close $21B Exact Sciences acquisition Monday - MedTech Dive
Abbott (ABT) Finalizes Exact Sciences Acquisition to Boost Cance - GuruFocus
Abbott to close Exact Sciences acquisition on March 23 - Investing.com
Exact Sciences and Abbott receive all approvals for planned merger - Investing.com
Exact Sciences Nears Completion of Abbott Acquisition Deal - TipRanks
Abbott acquisition of Exact Sciences set to close on March 23, 2026 - Abbott MediaRoom
Cancer test maker Exact Sciences is set to join Abbott March 23 - Stock Titan
Paradiem LLC Sells 55,579 Shares of Abbott Laboratories $ABT - MarketBeat
Park National Corp OH Sells 10,527 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Acquisition Of Exact Sciences Refocuses Growth On Cancer Diagnostics - simplywall.st
Abbott Labs Q4 2025: Revenue Miss, Device Growth & Exact Sciences AcquisitionNews and Statistics - IndexBox
1 magnificent dividend stock down 22% that's a screaming buy right now - MSN
1 Magnificent Dividend Stock Down 22% That's a Screaming Buy Right Now - The Motley Fool
1 Magnificent Dividend Stock Down 22% That's a Screaming Buy Right Now - The Motley Fool
CIBC Private Wealth Group LLC Decreases Stock Holdings in Abbott Laboratories $ABT - MarketBeat
AIA Group Ltd Raises Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (ABT) likely to benefit from nutrition segment recovery - MSN
Abbott Investors Ink $40M Deal Over Infant Formula Crisis - Law360
Futures Contracts for Abbott Laboratories Futures - TradingView
Selling pressure pushes Abbott Laboratories stock lower in today's trading - Traders Union
Abbott Labs Leaders, Shareholders Reach Formula Suit Settlement - Bloomberg Law News
Is Trending Stock Abbott Laboratories (ABT) a Buy Now? - Yahoo Finance
Abbott’s $21 Billion Exact Sciences Acquisition Supports a $179 Price Target - TIKR.com
Wilmington Savings Fund Society FSB Sells 25,557 Shares of Abbott Laboratories $ABT - MarketBeat
Danske Bank A S Takes $116.41 Million Position in Abbott Laboratories $ABT - MarketBeat
Coldstream Capital Management Inc. Increases Holdings in Abbott Laboratories $ABT - MarketBeat
Will New Diabetes and Cardio Data Shift Abbott Laboratories' (ABT) Chronic-Disease Innovation Narrative - simplywall.st
Abbott Laboratories Stock (ISIN: US0028241000) Hits Multi-Month Lows Amid Pullback: Buy the Dip Oppo - AD HOC NEWS
Abbott Laboratories $ABT Shares Purchased by Mariner LLC - MarketBeat
Mairs & Power Inc. Decreases Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock (ISIN: US0028241000) Shows Resilience Amid Healthcare Sector Headwinds, Tr - AD HOC NEWS
Mercer Global Advisors Inc. ADV Buys 79,707 Shares of Abbott Laboratories $ABT - MarketBeat
Focus Partners Wealth Has $71 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Fred Alger Management LLC Has $20.29 Million Position in Abbott Laboratories $ABT - MarketBeat
Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness and Modest Undervaluation Estimate - simplywall.st
Abbott Diabetes And Cardiology Updates Test Growth Story For Investors - Yahoo Finance
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.20%
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):